Deakin University
Browse
kanwar-ym155down-2015.pdf (3.47 MB)

YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells

Download (3.47 MB)
Version 2 2024-06-06, 01:30
Version 1 2015-03-19, 15:03
journal contribution
posted on 2024-06-06, 01:30 authored by SM Cheng, YC Chang, CY Liu, JY Lee, HH Chan, CW Kuo, KY Lin, SL Tsai, SH Chen, CF Li, E Leung, JR Kanwar, CC Huang, JY Chang, CH Cheung
The aim of this study was to determine the potency and molecular mechanism of action of YM155, a first-in-class survivin inhibitor that is currently under phase I/II clinical investigations, in various drug-resistant breast cancers including the oestrogen receptor positive (ER(+) ) tamoxifen-resistant breast cancer and the caspase-3-deficient breast cancer.

History

Journal

British journal of pharmacology

Volume

172

Pagination

214-234

Location

London, Eng.

Open access

  • Yes

eISSN

1476-5381

Language

eng

Publication classification

C Journal article, C1 Refereed article in a scholarly journal

Copyright notice

2015, John Wiley & Sons

Issue

1

Publisher

Wiley